Juyi Li1, Xiufang Wang2, Jian Chen3, Hongmei Zhang4, Aiping Deng1. 1. Department of Pharmacy, Key Laboratory for Molecular Diagnosis of Hubei Province, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China. 2. Department of Pain, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China. 3. Department of Information, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China. 4. Department of Endocrinology, Tongji Medical College, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abstract
Importance: Data are lacking whether patients with hypertension who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have increased severity or risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19). Objective: To investigate the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection. Design, Setting, and Participants: Retrospective, single-center case series of the 1178 hospitalized patients with COVID-19 infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020. Main Outcomes and Measures: COVID-19 was confirmed by real-time reverse transcription-polymerase chain reaction and epidemiologic, clinical, radiologic, laboratory, and drug therapy data were analyzed in all patients. The percentage of patients with hypertension taking ACEIs/ARBs was compared between those with severe vs nonsevere illness and between survivors vs nonsurvivors. Results: Of the 1178 patients with COVID-19, the median age was 55.5 years (interquartile range, 38-67 years) and 545 (46.3%) were men. The overall in-hospital mortality was 11.0%. There were 362 patients with hypertension (30.7% of the total group; median age, 66.0 years [interquartile range, 59-73 years]; 189 [52.2%] were men), of whom 115 (31.8%) were taking ACEI/ARBs. The in-hospital mortality in the patients with hypertension was 21.3%. The percentage of patients with hypertension taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32.9% vs 30.7%; P = .65) nor did it differ between nonsurvivors and survivors (27.3% vs 33.0%; P = .34). Similar findings were observed when data were analyzed for patients taking ACEIs and those taking ARBs. Conclusions and Relevance: This study provides clinical data on the association between ACEIs/ARBs and outcomes in patients with hypertension hospitalized with COVID-19 infections, suggesting that ACEIs/ARBs are not associated with the severity or mortality of COVID-19 in such patients. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic.
Importance: Data are lacking whether patients with hypertension who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have increased severity or risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19). Objective: To investigate the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19infection. Design, Setting, and Participants: Retrospective, single-center case series of the 1178 hospitalized patients with COVID-19infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020. Main Outcomes and Measures: COVID-19 was confirmed by real-time reverse transcription-polymerase chain reaction and epidemiologic, clinical, radiologic, laboratory, and drug therapy data were analyzed in all patients. The percentage of patients with hypertension taking ACEIs/ARBs was compared between those with severe vs nonsevere illness and between survivors vs nonsurvivors. Results: Of the 1178 patients with COVID-19, the median age was 55.5 years (interquartile range, 38-67 years) and 545 (46.3%) were men. The overall in-hospital mortality was 11.0%. There were 362 patients with hypertension (30.7% of the total group; median age, 66.0 years [interquartile range, 59-73 years]; 189 [52.2%] were men), of whom 115 (31.8%) were taking ACEI/ARBs. The in-hospital mortality in the patients with hypertension was 21.3%. The percentage of patients with hypertension taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32.9% vs 30.7%; P = .65) nor did it differ between nonsurvivors and survivors (27.3% vs 33.0%; P = .34). Similar findings were observed when data were analyzed for patients taking ACEIs and those taking ARBs. Conclusions and Relevance: This study provides clinical data on the association between ACEIs/ARBs and outcomes in patients with hypertension hospitalized with COVID-19infections, suggesting that ACEIs/ARBs are not associated with the severity or mortality of COVID-19 in such patients. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic.
Authors: Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher Journal: Circulation Date: 2005-05-16 Impact factor: 29.690
Authors: Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger Journal: Nature Date: 2005-07-07 Impact factor: 49.962
Authors: Jan Klimas; Michael Olvedy; Katarina Ochodnicka-Mackovicova; Peter Kruzliak; Sona Cacanyiova; Frantisek Kristek; Peter Krenek; Peter Ochodnicky Journal: J Cell Mol Med Date: 2015-03-12 Impact factor: 5.310
Authors: Renato D Lopes; Ariane Vieira Scarlatelli Macedo; Pedro Gabriel Melo de Barros E Silva; Renata Junqueira Moll-Bernardes; Andre Feldman; Guilherme D'Andréa Saba Arruda; Andrea Silvestre de Souza; Denilson Campos de Albuquerque; Lilian Mazza; Mayara Fraga Santos; Natalia Zerbinatti Salvador; C Michael Gibson; Christopher B Granger; John H Alexander; Olga Ferreira de Souza Journal: Am Heart J Date: 2020-05-13 Impact factor: 4.749
Authors: Renato D Lopes; Ariane V S Macedo; Pedro G M de Barros E Silva; Renata J Moll-Bernardes; Tiago M Dos Santos; Lilian Mazza; André Feldman; Guilherme D'Andréa Saba Arruda; Denílson C de Albuquerque; Angelina S Camiletti; Andréa S de Sousa; Thiago C de Paula; Karla G D Giusti; Rafael A M Domiciano; Márcia M Noya-Rabelo; Alan M Hamilton; Vitor A Loures; Rodrigo M Dionísio; Thyago A B Furquim; Fábio A De Luca; Ítalo B Dos Santos Sousa; Bruno S Bandeira; Cleverson N Zukowski; Ricardo G G de Oliveira; Noara B Ribeiro; Jeffer L de Moraes; João L F Petriz; Adriana M Pimentel; Jacqueline S Miranda; Bárbara E de Jesus Abufaiad; C Michael Gibson; Christopher B Granger; John H Alexander; Olga F de Souza Journal: JAMA Date: 2021-01-19 Impact factor: 56.272
Authors: Ravindra K Sharma; Bruce R Stevens; Alexander G Obukhov; Maria B Grant; Gavin Y Oudit; Qiuhong Li; Elaine M Richards; Carl J Pepine; Mohan K Raizada Journal: Hypertension Date: 2020-08-12 Impact factor: 10.190
Authors: Emil L Fosbøl; Jawad H Butt; Lauge Østergaard; Charlotte Andersson; Christian Selmer; Kristian Kragholm; Morten Schou; Matthew Phelps; Gunnar H Gislason; Thomas A Gerds; Christian Torp-Pedersen; Lars Køber Journal: JAMA Date: 2020-07-14 Impact factor: 56.272